MLYS - Earnings call transcript Q3 2024 | Mineralys Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to Mineralys Third quarter 2024 Financial Results Conference Call. [Operator Instructions].

As a reminder, this conference is being recorded.

It is now my pleasure to introduce Dan Ferry of LifeSci Advisors. begin. Please

Daniel Ferry

release replay Good call. welcome market After our A will we call will a for operator. quarter the prepared our section trading remarks, today's everyone, the hour after Q&A. quarter issued be conference approximately call our third XXXX the press afternoon, you, results to we and third website of X on today, its XXXX Investors Thank financial our and providing updates. business close available of of completion. After open

annual risks Before cautionary subsequent everyone differ specifically we company's the forward-looking these information today's about events. and statements contain to statements including XX, in stated the filings, obligation begin, forward-looking and the These I qualified press Form would statements our today, business. by we to by of from required statements materially our that except contained update that or these webcast to are uncertainties like remind implied associated forward-looking could call this forward-looking or conference with new on results any forward-looking in statements those in company. light Actual these note will November as and or by our release statements of only as Please law, report disclaim future XX-K opinions reflect revise SEC filings. due

the to Congleton, Jon turn over Chief of call to Jon? like Minerals Officer now Therapeutics. would I Executive

Jon Congleton

David clinical welcome everyone, quarter Chief an by Adam Good milestones. call our before with open financial will your up Corporate Dan. I'll you, our review Officer. Adam third Medical overview our recent today of Dr. and third Conference begin Then Rodman, Officer; questions. the afternoon, our for joined we Update the results Financial and Financial our and Chief quarter I'm programs Thank business, and to XXXX Call. Results Levy,

our pivotal clinical first throughout with then upcoming these things hypertension in several development kick an recently XXXX. our We safety completed as and treatment to off or we of When has medications. HTN made of standardized hypertension. or of the discuss background a the past anticipate therapy Mineralys months, used the half antihypertensive the of a is of resistant team Advance to X of lorundrostat evaluating advancing pivotal efficacy add-on enrollment want recap the uncontrolled trial, and I progress lorundrostat in treatment the for X milestones which

Subjects with include once announced characteristics once milligrams across daily. or to trial including XXX have more milligrams of black key X and were to more XX% and randomized XX equal race. or American BMI more the XX, than up than lorundrostat the in than daily, of than subjects the We to subjects arms, the the are XX% XX subjects African subjects daily once placebo, or of at milligrams possibility lorundrostat greater titrate are women roll of XX% a

sex. terms with of demographics, across diversity across of race steps of the subjects to in representation this goal showing broaden and Notably, in to different better extra trial the provide a populations we equivalency took the

rigorous pressure was of has monitoring gold the rates ABPM, which XX-hour trial trial the has measurement placebo compared or blood XX-hour white designed other this in reminder, the managed with Clinic responses and for based pressure on lower and a coat ambulatory standards. As most approaches. collaboration standard to is Cleveland utilizing shown better historically blood be will The measurement hypertension

protocol. as lorundrostat to been participant participants dipping track role medication which to partner is the that to pressure ensure and play compliance ABPM assess which utilizing blood Additionally, with under cardiovascular adverse and outcomes. helps take a nighttime called trial smartphone-based the to manage have XX-hour shown status, risk and has nighttime Advance-HTN all blood a AiCure, in ability pressure technology prescribed

important lorundrostat, endpoint primary active change to planned that pressure in of enhanced cohorts includes this trial. in were allow Target-HTN Subjects the XX-hour placebo. the obesity or versus the II distribution identify at baseline trial response several resistant predictors arms effort each from for hypertension analysis in demonstrated The uncontrolled was is as for population. analysis test each with balanced systolic across in a perform week X ambulatory trial subset XX of blood Phase stratified an The such to us of to providing formal to

unmet physicians. hypertension, rapid the Positioning will We for need robust positioning and increased expanded by patients an efficacy important uncontrolled payers and for obese who believe demonstrating and at lorundrostat highest be market are hypertension will medical area resistant risk lorundrostat provide confirmed of access in uptake cardiovascular opportunity.

lorundrostat, line we as and we with other the for including to experience or plan who using likely benefit. positive lorundrostat announcing toolkit top XXXX. hypertension long-term to intelligence more to individuals addition, are explore of We data, targeting in to accrue March anticipate resistant predictive we to expand which data uncontrolled with sharing negative the artificial and precision to factors look forward drive continue In clinical

at ahead is evaluating real-world our be added to when setting announce trial to trial With Launch needed week top forward failed as to to of on to their to in therapy trial, once prescribed III their to with results a of guidance daily X data with subject's on this of treatment X. for enrolled X completed resistant a we or of lorundrostat Phase lorundrostat control who were background existing half subjects trial. existing control lorundrostat daily is Subjects We excited we to confirmatory prescribed once line in hypertension Launch-HTN hypertensive just of medications. designed a in for HTN Moving a to prescribed enrollment schedule, lorundrostat regimen. these pulling the either updated treatment the XX achieve a which Launch-HTN, pivotal trial of add-on titrate or the to placebo, treatment with hypertension a were our previously once milligrams the that randomized X failed as second blood ago completed pressure to who mid-first weeks X XX pressure enrollment few blood X milligrams in achieve of objective to in uncontrolled milligrams of XXX option daily XXXX.

endpoint and pressure the be to primary believe relevant as to office this measured providers. clinical trial by to is as week well status automated clinical that This reflective trial X change for well placebo. at compared of such lorundrostat. utilizing at blood an measurement systolic as primary We existing be for to pooled lorundrostat is care pressure subjects the the in as will powered will for blood practice this The subset the endpoint inform is X added weeks analysis primary in-office regimen label the when treatment real-world trial of XX-milligram BMI

program patients resistant pivotal are Phase clinical ongoing, the Stage to with anticipate we XXXX. Explore trial In or top in hypertension, Enrollment with II II addition we SGLTX connecting announcing lorundrostat uncontrolled chronic lorundostat for inhibitor treatment line CKD in data and background to the hypertension, to of in is when our second III added disease. in kidney quarter

CKD evidence approximately the II This reducing and treatment. subjects disease inhibitor lorundrostat trial chronic Explore subjects for to III in enroll potential background will designed demonstrate supportive on for of in the benefit to kidney stage with within-subject benefit proof-of-concept trial provide blood CKD. stabilized pressure XX comparison of with as GLTX a hypertension

a of October Adam, to KOL hosted we is section just the I to replay want of everyone turn on I remind call the Before still event, the XX the Mineralys over available website. Investors that on

McGill Medical Dr. field including us Luke Lofton We fortunate potential change Cleveland valuable the the current on and the Center, Rhian for the and lorundrostat are well to in Health call, Vanderbilt insights James the of treatment hypertension very University Touyz need Be paradigm. leaders the Center. join to uncontrolled Clinic; University offered and Professor unmet as Dr. as have of hypertension resistant on X of medical Luther

pivotal the of designs. a ongoing and their included also trials HTN We detailed and Launch HTN Advance review

I will the call over now to results quarter. to our Adam review for the financial turn

Adam Levy

I quarter results. Good portions third select XXXX our you, will of Thank everyone. John. Today, financial discuss afternoon,

ended will November million December found fund quarter well XX. and as planned investments September The to support be We its as its Form $XXX and of XXXX. corporate SEC operations with Additional as details cash, million that which as can with tomorrow sufficient be of XX, XX-Q, cash XXXX. cash, filed will of equivalents $XXX.X XX, in be investments our cash trials the the equivalents to clinical current believes company compared XXXX, into

as increase ended primarily the in and XX, R&D R&D $XX.X the the The initiation was accrued research supply, XXXX, development resulting expenses additions of quarter increased of million September by program the $XX.X XXXX, and for and million were preclinical in in stock-based same $X.X million to expenses $X.X increases and for manufacturing million lorundrostat costs costs, expense and XXXX. quarter in clinical of in headcount, regulatory clinical driven salaries to higher of other in of the $X.X pivotal compared in compensation to due second million from compensation quarter expenses. bonuses increases million $XX

compared expenses quarter in year. $X.X The for the headcount, prior million to and to expenses. accrued offset and by XX, $X.X September XXXX G&A of higher to expenses were G&A quarter for million million the in million the due same $X.X ended was increase fees increased in higher in salaries decrease administrative of in additions bonuses increases other compensation $X.X from $X.X professional million resulting a expense stock-based compensation partially and primarily

million the market quarter for XX, earned in XXXX, same ended the U.S. quarter The $XX.X open was With for was to investments for of was I The company's million described to income to for the Total was factors on same increase the I'll to Net Operator? the the million funds ask other and primarily that, treasuries. primarily quarter $XX.X compared $X.X loss ended the $X.X XXXX. September increased September XXXX. to interest attributable earlier. XXXX, million call XX, operator the questions. for compared quarter of attributable increase money

Operator

[Operator Instructions].

DiFiore with is ISI. Michael Evercore Our first question from

Michael DiFiore

the all on me. Congrats for progress. Three

the you were Any wasn't X dipping looking the that group. then one Target results patients white the HTN any in have in be code noticed nocturnal color sensitivity there XX-milligram even pressure QD at analysis, nighttime great. would that First to reviewing explain in blood just hypertension I the and data the And eliminated, set, weeks at after X is follow-ups.

David Rodman

Yes.

Dave this Rodman. don't I that So question. is Why take

get less a noise. lot a a for you're untreated you XX-hour factor first in value daytime, nocturnal measurements driver get is absolutely particularly you of of into outcomes big cardiovascular you right because first nighttime measurements, and But big and mentioned, all, to data, night the So that get as ambulatory much of a adverse important times all, hypertension also quieter so and you lot risk segmented MACE. is,

was XXX-milligram response to nighttime hypertension, the comparable taken point seen had in little very first the measurements what There, were I if evening. code and where dose in morning lorundrostat cohort though we was in the those the So can wakefulness, to even was the you white to

And would was that's white so lower or ABPM because the a you they little a to AOBP blood who of patients high what hypertension. XX-milligram so-called with of is very there more on expect. a had than to proportion kind have coat pressure appear interpret problematic The

people daytime. analysis So to subtract the about we it when that, did reduction had was those out and sensitivity to to a XX% we do all compared

that's controlling too the looking the think for we'll unlikely true But XXX-milligram trial. and in small. guide I it's the think I better a do in any is got numbers event, post. that probably because be

accurate the have we'll So that. for answer

Michael DiFiore

that unblinding thing. data Dave. separately, set. at my a the relative safety there of And sinus ask the would in potentially study at And one there reviewing just an the we're the the X case is And those safety of Any then of database, was like it, that question of just how MAD X explanation great. could be noticed case early because dysgeusia margin be Got of big helpful. set, a Very follow-ups milligram. And data unblinding, my functional also NOAEL XXX And to Phase same one tachycardia I milligrams. milligram? me I as is XXX XX trial, type was first-in-human are, in SP-X

Jon Congleton

So well, one the first -- take the first. first I'll

milligrams. XXX well How causes that's this acutely, drug a work volume loss. So does dose, big pretty and

out response is the urinate water, you and that sodium tachycardia. So sinus to

or So when what you that's volume get depleted, dehydrate happened.

a of not it's too effect much volume volunteer depletion. really finding. pharmacodynamic having So a safety a It's healthy

hypertensive we in read that doses, lower these so the expect And especially don't through at patients. to

or second I problem know. Now hasn't didn't functional not, it question, one. We our haven't unblinding just that whether on got been idea again your no I just it's seen else, in don't dysgeusia, Mike? trials. Anything a it

Michael DiFiore

No, that's it. Appreciate it.

Operator

from is question Goldman next Richard Our with Law Sachs.

Jin Law

A me. of couple from questions

the adherence do that enforcing proactively Advance, you HTN? you can tracking in what Advance discuss and improve The target for much first you And rate one guys is how adherence. are adherence for think is Can HTN?

David Rodman

Advance the trial what's was versus question HTN or... the in Target the an rate adherence So

Jon Congleton

for restate No, you is you're question can Rich, what Sorry. the looking your again? goal

Jin Law

Yes.

you guys tracking you for not Advent, you enforcing and target proactively for are guys didn't -- So do HTN. guys adherence, are doing that but

So the do much tracking just for target into adherence as you curious could think enforcing? improve by you rate to that proactively CN what and was how see HTN -- Advanced move and

David Rodman

question. Okay. Good you. Got

not. So the -- the -- ultimately thing was the did that's counts taken came -- only but didn't some that we piloted really method really do how in they AI We cure didn't technologies, their was to people we're up now. pill if we when data drug or see to choosing we ended had use using we

you're counts notorious because know information accurate doing any because ineffective you it. give can't I people pill So are

sink might adherence, they not but the are or much. in also trial, in whatever. that launch out dump so or telling the actively we're them in terms But of reaching And doing them we supporting just

than other so normal reminders. And the

non-adherence So problem there, looks I much think is to a question, at is in how a which responses. that analysis do terms there your -- of subset we're going and

sensitivity than more people we'll or not. XX% took So who a analysis do on

target, So an but your really too I to the comment can't will on much question. we answer have

Jin Law

then it. I And see. another question. Got

assume in it both absolute for with controlled. how measurement. study the Is compared You guys are placebo lower to that value that well safe similar HTN? about you adjusted AOBP, very a the ABPM How if just SPP change placebo do mentioned to the think would and example, is and Advance ABPM

Jon Congleton

it's averaging of give of Target I'll methodologies We more minus actually bit saw prior X-millimeter that placebo with a know that. a quiet from room standpoint saw see trials such with or typically quick We on higher mercury time measurement Rich. a you with X. little because and HTN as measurements SanCor heads We Well, different from single have up we It's used and a millimeters a it's a use because office. variability AOBP, that XX-hour ambulatory the figures maybe in XX-hour that, about plus that with unattended that, X X, point change. in technique the doing X last the studies than mercury see around

measurement. have advance to ambulatories, the and in repeat our standpoint, our have we're the AHA, only also recommendations we from technique So for following in-office home. office, not from within the XX continuing in along -- primary

confident So practice for launch different HTN. that's the done based Target work -- Then we the advanced have on measures within techniques. and we'll X within and -- the we HT with HX in-office for controlled we've that feel that the we've we variables so that different use

David Rodman

of mercury in the level tend tends pressure. that Rich, with in drugs have proportionate measurements one other lower to the millimeters they the comment ABPM, which don't nighttime, is because sleep is X average to be hypertension baseline be apnea, about say response people to lower here that blood and to

can a down So a you baseline less, smaller response. lower little have bit you you -- have so blood go have if pressure, you

so -- ABPM John most millimeters have X the or numbers mentioned, effect are shifted when in ABPM, there's versus there. it's smaller effect variability you X you placebo-adjusted more just And So as say up then placebo treatment but the with do AOBP. people those

to wanted to know, noisier. it So than Maybe pass on. more but bit was they're you little just that a just

Jin Law

lot. I that think a No, helps

about once you're for be that X to absolute X% saying basis, So an about but X%? should on adjust placebo, you or so

David Rodman

placebo what AOBP, that's it to or pretty would to I've general, think, X in range. all big our acceptable first seen in a with the a sorry, I Baxter millimeters study. small. to ABPM, In difference if I it's look X were mean, the -- of to X X Target their what to is sure had X, one We up be because Not or mercury in up the measurements, that be with they of the set, multiple is we ABPM even is enough literature. had will up your trial, in so X. study, going X. I you say effect X, at puts that and

put -- can. work we making best sure and we lot the a of data into So get we

Obviously, more your I'm trials to you per more you se, but tend have I not when get bigger question gives you to sites, slightly and sure hope that answer understood variability the I needed. you

Jin Law

Okay. Got it. one And just then question. final

XX. mentioned greater XX What for is power XX% assumption You XX% guys like greater number. that, than with greater patients from BMI BMI less and than than than group XX that the

mentioned XX% the I group. think a powering assumption guys for overall you

assumption to want down that go subgroups? just I prespecified powering see like these you what look to So when

Jon Congleton

for we for thanks Advance-HTN power greater questions. relative a X-millimeter And Launch-HTN, analysis Rich, for of same XX% power at the the in to reduction. subset XX% any this overall disclosed calculations. power change haven't point placebo, Yes, is than mercury time the

Operator

Samimy is Stifel. Our with next question from Annabel

Annabel Samimy

I clarify just of things. a want to couple

then Advance-HTN, weeks endpoint at to I'm weeks, is with X titration runs titration if it weeks with correctly. the launch but and up weeks there, at endpoint XX primary X XX your at reading the has For presentation primary

a So that introduced noise given the it to meds. X scenario? there background that of kind weeks be that the with I might not in to is response for placebo is how sufficient? possible and weeks with managing why Are X variability. more I are guess, additional XX going results guess confounding sufficient real-world weeks -- possibly you be run that background that the separation

Jon Congleton

question. the appreciate Annabel, Yes,

Target medication in treatments. of on I as allow to far think stay their to There very you -- X to confirmatory subjects the background antihypertensive of know, we as X similarities it's Target-HTN. a are of as lot as study in a Launch, Launch-HTN important to much as think construct

to meds. Target-HTN and placebo. of background majority plus existing get them the on effects. in using week period we that vast about X XX%, we X, What compliant effect technology by run-in X-week techniques, same We're of week at or used that minus, in and When Target. their same Launch-HTN, have the We was saw AOBP we the

not within the So we readout. We're at And of one we're course to on HTN X-week blood that significant data missing highlight within in both the just half target, the potential any between HTN, on diuretic distinctions biggest time all I'll Launch week definitely just and pressure synergy design, the a going studies comfortable we X. saw by subjects that, in a what diuretic. is maybe in about were in Advance based and saw diuretic a where on that be reduction X that Target really with are subjects

treated I the profile Plus Launch-HTN of So anything. at point time that arm. looking XX-week design of the confirmatory in as this we're that think factored secondaries, feel to arena and XX will we we don't upside part going of missing to the for arm XX-milligram XXX-milligram be we've within be both the

Annabel Samimy

And obese you between -- Okay. Got back just is possibility it. separation nonobese, versus see mean, I a for for last to the significant but haven't the to statistical question I X? -- there go disclosed to powering a know

Jon Congleton

be week X we'll moving Target-HTNand The at in from of looking primary the prespecified analysis. endpoint for Launch. for think XX as and of power to both I not power week Launch-HTN Well, primary subsets the we but subset was primary Advance in was those did in these benefit

the power have we're the statistical to saw that. get trend going we part HTN. to be that's Target if But prespecified but evidence feel again, target reconfirms able to the we to to got as be didn't so data to able going very as on confident that And of analysis we've be we the to HTN,

Annabel Samimy

actually to we the getting also they blood should is should Or so dose looking period? a in response for it. exposure any be control response XXX have And be and looking milligrams to -- opposed pressure dose we Got as response like just this can words, other Okay. should for clarify, between we the about XX patients right expect more just the arms? to then

David Rodman

What Yes. good a question.

goal thing right? let's So -- X in at at be group be Advance and talk XX -- and a They'll that hadn't there'll be XXX. same true they the There'll be arms, to There'll in look weeks at group is placebo ways -- a group. weeks X if stayed on reached Launch. to be Advance, XX that. a just there'll then about got that escalated

at And might the absorb they a didn't at lot have would that. so a XXX whatever, aren't it production have of enough if If that. XXX fix because well didn't aldosterone and people than suppressed if XX people high -- or fix they exposure just XX completely

So downstream to a its we sure we at which looking individual until while. come won't mechanistic for exposure biology biomarkers, start for won't drug know maybe if or

So I hope that answered your question.

right. absolutely You're

Operator

Our Wells question with Fargo. Mohit next Bansal is from

Unknown Analyst

Mohit. is This on for Sadia

the wondering they remind you've are outlined enrolled the of terms trial. patient -- expect So African-Americans targeting launch these rates patients percentage should differences of we and any Advance demographics for obese or will these? -- how I'm percentage us to demographics that in the the similar target? you And in population of be if you're in of can compared Advance was in in

Jon Congleton

Yes.

it We African-American that haven't XX, do and the believe Target demographics I We was Black meter about average we mean per believe HTN is updated Target HTN. of population, in was square had HTN, XX%. the around future. kilograms XX%, BMI the it may Launch what was I in on

we from what in saw dissimilar terribly not So Advance.

hypertension I and because Caucasian as important typically case really far that's as in what patients all think probably to representation the Advance African-American both Target not that's that and point it's fair Black Black you beyond anti-hypertensives. equivalency African-American to always see for between out with show

can see our wanted to to part tool able precision evaluate as kit. you Sometimes a We that response. of disparity be in

effect. questions going far launch-HTN, dilute the it a study. that As We've global as is to gotten is BMI

is obesity that to holds correlation counterpoint pretty with globally. the hypertension the strong think I

don't study Target going Target. we is a terribly what dissimilar makeup global HTN in for of too that though saw we from so even concern the is Launch-HTN look a have U.S. And versus to it alone

David Rodman

tends and population, between of the discussion. be Black well admixture There's same as -- just could and was a one difference add I Caucasian to African-Americans have Africans which hit the very the European if a nice genes. of thing, doesn't Jon, as that

are on lower more sensitive to hypertension. not whole So in That's Alto Europe. true aldosterone, super African-Americans produce the levels of

so And will. we we are between have to have X, sites, distinguish and since those going European we to

Unknown Analyst

That's versus trials, with enrolled in assumption that number how for being the other was you then launch Do geographies about response? launch? part Got And be the the to higher of you placebo it. and -- a sites your are powering helpful. of are there respect and thinking think could placebo And that response Launch?

David Rodman

So at Launch is pretty much super big looking powered because study it's such and size. effect a similar

if decrease well, trial an is effect, question has. the and, is problem therefore, the affect if that size there's be significant of presumably the introduce a So answer that both upward going power. a shift would is won't in it And the more which it variability placebo your with from powering arms, to

Operator

Our Rami with Capital. is Lifesci next question from Katkhuda

Rami Katkhuda

me. a potential eGFR a criteria, the in patients recruiting on inclusion target, couple hyperkalemia Advance Just of affect in studies? have to those Launch does quick ones lower and rates pivotal the I to than the from all are guess that at based

Jon Congleton

We You're above on advance. target GFR right, XX% at comfortable XX Launch the going and in based for We to Rami. for that. both looked down were

HXX, allowable. tell arm the I data a indicates. too see to point. dose actually QD. XX-milligram the modest where really have know study what milligrams Target and the an going this in to we potassium XX it's at Explore we're would saw to from change to think what early to XX is of We'll we reduced The But eGFR an similar [indiscernible] down you We've with CKD expect arm.

want related think benefits well I pharmacological as on population and the within both we it's that profile, effect potassium. cautiously to to the as move sodium investigate safety we that lorundrostat specifically as in this

Rami Katkhuda

a of being analysis advanced. lot And do were of who compliance Makes trial is those you not? patients are Do to those it. throughout sense. is of not who an the in obviously, versus plan launch, compliant as kind Got it then enforced in

Jon Congleton

active And next-level also a really really subjects placebo take for AI but it's of They compliant just been The film patients advancement. That have it. they're the is really their to picture it's being out validated, only or Yes. consuming -- a that of are randomized. but advanced we reaching background are meds, also and aware, how not reminding we're those you technology know, do of going of be XX% and have compliant that take in the cure to may either they're the to not ensure in if compliance, launch ones, themselves we as advance, technique those those the looking both being Launch, technology above importance in XX%. but is prespecify subjects I it's an for them that, we analysis used drug not, proactively to below believe at in not

So as prespecified analysis. a we'll have that

way advanced technology is technologies Target being with full are impact. manipulate do that I that they pill. do trying it with know things So HTN, the to a are we was that that at and look most help in compliance to compliant build can other patients kind can of pill us the of important completely standard to not just to less we think use And can to words, on proof. We're point, counts Dave's nice In that. but progressively help but saw we it, patients one really

that think I hypertension of addressed So know studies currently we kind of we're using one in an that we've been technology validated questions has to with other the issue studies bigger help contemporaneously. ensure state-of-the-art these really

Operator

from Our Wainright. Caufield next H.C. question is with Matthew

Matthew Caufield

for that but event, meaningful. of to same the better kind X be you launch Does was range the ambulatory to KOL during that millimeters in, on for translate or advanced touched HTN, potential X successful? power to be it the ranges mentioned with BP this clinically of target and So considered explore benefit could

Jon Congleton

in that X-millimeter hypertension I KOL call. they resistant started is as or because X reducing I I far uncontrolled call really mercury as Matt, a the appreciate think truly particularly think cardiovascular even was highlighting fact by risk. change, patient Yes the instructive or Yes, the hypertension meaningful

important always it's to into that context. So put

on absolutely in [ to X the think alluded is to that often population point. Luc I ] a X-millimeter broad

add the certainly physicians, truly a systolic. from transformative outcome in within to to clear would with and with that market. X-millimeter Advance typically that further get within available always that's saw guided research There's Launch, when we've that, them. XX-millimeter treatments that standpoint. for fourth in on meta-analysis realm to payers correlation important a Based based Target and done X- generic in a an third you show currently replicated And mercury the on if the HTN reduction the line that's risk reduced We've market what's we with mercury agent, or change you of be meaningful and

advances like mercury [ Apperson,] to reduction. New denervation renal X found have XXXX or X-millimeter

to And So XX that well their that even what that's a And subjects ultimately, more prescribed X goal. risk population something studies the more replication these their is truly meaningful. that shift of cardiovascular as the we'll but be subsets foundational is becomes percent a having patients profile. as not goal the effect is we getting pronounced such an as and transformative. in looking goal at placebo-adjusted find production, And only absolute below obese both and have if within BP getting of to of actually

Matthew Caufield

an renal well. standpoint, think it SGLTX in applies does that derisked that benefit not combination say BP I Yes, we a a investigating with you an on benefit does. function explore only CKD Very certainly Explore helpful. really an of think is as as And well? from to now would ASI what but is It

Operator

back further closing questions to for turn the like in queue, remarks. would over Jon no With conference the to I

Jon Congleton

today. advancing We're you about and and to you, we've thus look for excited of call. XXXX our Thank forward program about programs, the far we continues we everyone milestones XXXX. advance. in remain very progress enthusiastic in made to half clinical operator, joining thank the planned With that, will first close for We as to updating data our upcoming pivotal for you Lorundrostat the the us

Operator

you. conclude today's This Thank does conference.

You may at your disconnect thank you time, for this and participation.

Mineralys Therapeutics (MLYS) 11 Nov 242024 Q3 Earnings call transcript